# US 2015/0307605 A1 · Purified antibody composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0307605 A1
- Document ID: US20150307605A1
- Status: Published application
- Kind: A1
- Application number: 14/796,779
- Filed: 2015-07-10
- Published: 2015-10-29
- Earliest claimed: 2006-04-05
- Assignees: AbbVie Biotechnology Ltd.
- Applicants: AbbVie Biotechnology Ltd
- Inventors: Min M. Wan; George Avgerinos; Gregory Zarbis-Papastoitsis
- Web page: https://patentgrep.com/patent/US20150307605A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 1/18: Ion-exchange chromatography
- C07K 1/20: Partition-, reverse-phase or hydrophobic interaction chromatography
- C07K 1/36: by a combination of two or more processes of different types
- C07K 16/065: {Purification, fragmentation}
- C07K 16/241: {Tumor Necrosis Factors}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

## Claims

### Claim 1

A method of treating a disorder in which TNFα activity is detrimental in a subject, the method comprising administering a liquid composition comprising a therapeutically effective amount of adalimumab to the subject such that the disorder is treated,
wherein the adalimumab is produced in a Chinese Hamster Ovary (CHO) cell expression system;
wherein the disorder is selected from the group consisting of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and juvenile rheumatoid arthritis; and
wherein the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.84 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises:
i) diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5,
ii) adding dextran sulfate to a concentration of 0.035 μg/mL and incubating at 37° C. for six hours,
iii) adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and
iv) measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cathepsin L activity is no greater than 1.3 RFU/s/mg of adalimumab.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cathepsin L activity is no greater than 1.0 RFU/s/mg of adalimumab.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cathepsin L activity is no greater than 0.6 RFU/s/mg of adalimumab.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cathepsin L activity is no greater than 0.85 RFU/s/mg of adalimumab.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cathepsin L activity is no greater than 0.9 RFU/s/mg of adalimumab.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is packaged in a pre-filled syringe.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition comprises 50 mg/ml of adalimumab.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition is suitable for subcutaneous injection.

### Claim 10 (depends on 1)

The method of claim 1, wherein the diluted composition has an adalimumab concentration of 20 μg/ml.

### Claim 11 (depends on 1)

The method of claim 1, wherein the diluted composition has an adalimumab concentration of 50 μg/ml.

### Claim 12 (depends on 1)

The method of claim 1, wherein step i) of the cathepsin L kinetic assay comprises diluting the composition 600 fold.

### Claim 13 (depends on 4)

The method of claim 4, wherein the composition is packaged in a pre-filled syringe.

### Claim 14 (depends on 4)

The method of claim 4, wherein the composition comprises 50 mg/ml of adalimumab.

### Claim 15 (depends on 14)

The method of claim 14, wherein the composition is suitable for subcutaneous injection.

### Claim 16 (depends on 4)

The method of claim 4, wherein the diluted composition has an adalimumab concentration of 20 μg/ml.

### Claim 17 (depends on 4)

The method of claim 4, wherein the diluted composition has an adalimumab concentration of 50 μg/ml.

### Claim 18 (depends on 4)

The method of claim 4, wherein step i) of the cathepsin L kinetic assay comprises diluting the composition 600 fold.

### Claim 19 (depends on 1)

The method of claim 1, wherein the disorder is rheumatoid arthritis.

### Claim 20 (depends on 1)

The method of claim 1, wherein the disorder is Crohn's disease.

### Claim 21 (depends on 1)

The method of claim 1, wherein the disorder is ulcerative colitis.

### Claim 22 (depends on 1)

The method of claim 1, wherein the disorder is ankylosing spondylitis.

### Claim 23 (depends on 1)

The method of claim 1, wherein the disorder is psoriatic arthritis.

### Claim 24 (depends on 1)

The method of claim 1, wherein the disorder is psoriasis.

### Claim 25 (depends on 1)

The method of claim 1, wherein the disorder is juvenile rheumatoid arthritis.
